<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920669</url>
  </required_header>
  <id_info>
    <org_study_id>AP2014-50103</org_study_id>
    <nct_id>NCT04920669</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine in Erector Spinae Block in Postoperative Analgesia</brief_title>
  <official_title>Can Dexmedetomidine Improve the Analgesic Duration and Efficacy of Erector Spinae Plane Block in Breast Cancer Surgeries?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohamed Elsayed Hassan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      60 female patients scheduled for breast cancer surgeries, allocated in 3 groups for erector&#xD;
      spinae block with bupivacaine and erector spinae block with dexmedetomidine added to&#xD;
      bupivacaine and control group. During anesthesia: total intraoperative fentanyl required will&#xD;
      be recorded. After surgery the first time of request for analgesic will be recorded. after&#xD;
      request of analgesia all patients will be connected to PCA device containing morphine&#xD;
      solution, the amount of morphine consumed during the first 24 hours will be recorded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 female patients scheduled for breast cancer surgeries, allocated in 3 groups for erector&#xD;
      spinae block with bupivacaine and erector spinae block with dexmedetomidine added to&#xD;
      bupivacaine and control group. During anesthesia: total intraoperative fentanyl required will&#xD;
      be recorded. After surgery the first time of request for analgesic will be recorded. after&#xD;
      request of analgesia all patients will be connected to PCA device containing morphine&#xD;
      solution, the amount of morphine consumed during the first 24 hours will be recorded. Other&#xD;
      secondary outcomes are numerical rating scales and incidence of opioid side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first request of analgesia</measure>
    <time_frame>The first postoperative day</time_frame>
    <description>Time from recovery of anesthesia till first request for analgesia to relive pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total morphine consumption in first postoperative 24 hours</measure>
    <time_frame>First 24 postoperative hours</time_frame>
    <description>The amount of morphine required to relieve pain will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative fentanyl requirement</measure>
    <time_frame>During anesthesia</time_frame>
    <description>The amount of fentanyl required during anesthesia will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical rating scale</measure>
    <time_frame>The first 24 postoperative hours</time_frame>
    <description>Numerical rating scale (from 0 to 10, where 0 represents no pain and 10 represents the worst imaginable pain) will be recorded in different time intervals during the first 24 hours after surgery</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>erector spinae block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>erector spinae block with 20 ml bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>erector spinae block + dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>erector spinae block with 19 ml bupivacaine + dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard general anesthesia without any block</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>erector spinae block with bupivacaine</intervention_name>
    <description>Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%</description>
    <arm_group_label>erector spinae block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>erector spinae block with bupivacaine + dexmedetomidine</intervention_name>
    <description>Patients will receive a sonar-guided erector spinae plane block with 19 ml of bupivacaine 0.5%+ 1 ml dexmedetomidine</description>
    <arm_group_label>erector spinae block + dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed and dated informed consent form&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Female, aged (18-70) years&#xD;
&#xD;
          -  Belongs to American Society of Anaesthesiologists physical status class II.&#xD;
&#xD;
          -  Scheduled for breast cancer surgeries.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal.&#xD;
&#xD;
          -  Local infection at the site of the block.&#xD;
&#xD;
          -  Cardiac dysfunction (ejection fraction &lt;45%).&#xD;
&#xD;
          -  Preexisting neurological or psychiatric disease, communication difficulties, inability&#xD;
             to use the patient-controlled analgesia (PCA) device.&#xD;
&#xD;
          -  Allergy to one of the study drugs.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Coagulopathy (PC &lt;60% and platelet count&lt;100.000).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed E Hassan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute - Cairo University - Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed E Hassan</last_name>
    <phone>00201009921645</phone>
    <email>msh.hamada76@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed E Hassan, MD</last_name>
      <phone>00227370914</phone>
      <email>msh.hamada76@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Mohamed Elsayed Hassan</investigator_full_name>
    <investigator_title>assistant professor of anesthesia and pain relief</investigator_title>
  </responsible_party>
  <keyword>Erector spinae block.</keyword>
  <keyword>dexmedetomidine.</keyword>
  <keyword>Postoperative analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

